ClinicalTrialsFinder
RecruitingPhase 2NCT05661643

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

A Phase 2 Study to Evaluate the Efficacy and Safety of Temozolomide in Advanced Gastrointestinal Stromal Tumor Patients With SDH Deficiency

Sponsor

Asan Medical Center

Enrollment

29 participants

Start Date

Jun 28, 2023

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Stromal Tumors

Summary

The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Temozolomide capsule for people with gastrointestinal stromal tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTemozolomide capsule

Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)

Locations(1)

Asan Medical Center, University of Ulsan College of Medicine

Seoul, Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05661643

Related Trials

Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

NCT076183772 locations

Integrated Cancer Repository for Cancer Research

NCT0201269942 locations

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT071712031 location

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

NCT059058871 location

GIST Oral Paclitaxel(Liporaxel)

NCT063263461 location